Lilly Claims Proof Of Concept For Neutralizing Antibodies In COVID-19 Therapy
Executive Summary
Analysts called the interim data from a Phase II study of LY-CoV555 mixed, but Lilly insists that it has demonstrated a therapeutic role for neutralizing antibodies in fighting the novel coronavirus.
You may also be interested in...
Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.
Lilly’s EUA Timeline For COVID-19 Combo Antibody Depends On Safety Data, Manufacturing
Single neutralizing antibody moves to US FDA with data showing reduced hospitalization, while Lilly’s EUA filing for two-antibody combo awaits safety data and more certainty about production capabilities.
Lilly Seeks EUA For COVID-19 Antibody, Unveils Positive Combo Data
Following last month’s data showing reduced hospitalization risk with single neutralizing antibody therapy, Lilly now has data showing a two-antibody combo reduces COVID-19 viral load significantly.